Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression analysis of Triple-negative breast tumors from young and aged mice

ABSTRACT: Gene expression analysis of Triple-negative breast tumors from young and aged mice

PROVIDER: PRJNA540422 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Triple Negative Breast tumors: SPARC Positive Tumors vs SPARC Negative Tumors

Project description:The aim of this study was evaluate the transcriptome changes in the comparison between triple negative tumors with increased SPARC expression and triple negative tumors with decreased SPARC expression according to Nagai et al., 2011 (Breast Cancer Res Treat (2011) 126:1–14) The results generated could be of particular interest to better define the prognostic impact of SPARC expression in triple negative breast tumors

2018-07-01 | GSE98931 | GEO

Gene expression analysis of Triple-negative breast tumors from young and aged mice

Project description:Whole tissue RNA-seq analysis of mammary tumors from old (>12 months) and young (8-10 weeks) of mice after treatment with isotype, anti-CTLA4 or anti-PDL1 treatments.

2020-04-05 | GSE130472 | GEO

Transcriptome analysis of ER+/PR+, ER-/PR+ and triple negative breast tumors

Project description:The goal of this study is to analyse whether ER-/PR+ breast tumors could be transcriptionally different from ER+/PR+ and/or from triple negative breast tumors

2021-01-26 | GSE162332 | GEO

Gene-expression molecular subtyping of triple-negative breast cancer tumors

Project description:Gene-expression molecular subtyping of triple-negative breast cancer tumors

| PRJNA400182 | ENA

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Project description:This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative breast cancer (currently enrolling only patients with triple-negative breast cancer since 6/8/2007). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving 7-hydroxystaurosporine together with irinotecan hydrochloride may help kill more cancer cells by making tumor cells more sensitive to the drug.

| 2007227 | ecrin-mdr-crc

Transcriptome profiling of tumors from Kenyan triple negative breast cancer (TNBC) patients.

Project description:Triple negative breast cancer is an aggressive phenotypic breast cancer characterized by ER negative, PR negative and Her2 negative immunohistochemistry status. We embarked on a study to explore the transcriptome of Kenyan TNBC patients and identify potential biomarkers specific to Kenyan population. The transcriptome sequencing of tumors from Kenyan TNBC patients and comparisons with African American and Caucasian TNBC transcriptomes revealed several interesting targets and dysregulated pathways.

2021-04-28 | GSE142258 | GEO

Young and aged mouse bladders

Project description:Young and aged mouse bladders

| PRJNA629290 | ENA

Expression data of patient-derived triple negative breast cancer xenograft tumors

Project description:Triple negative breast cancer (TNBC) is an aggressive subtype that lack targeted clinical therapies. In addition, TNBC is heterogeneous and was recently further sub-classified into seven TNBC subtypes that displayed unique gene expression patterns. To develop therapeutic treatment regimens, we established seven patient-derived xenograft models from TNBC tumors. These xenograft models not only retained the histology and clinical markers of the corresponding patient tumors, but also bearing the same mutations and deletions identified in the patient tumors. Moreover, as part of evaluation of these models, we performed microarrays on the xenograft tumors to assess their TNBC subtypes.

2014-03-21 | GSE47079 | GEO

Gene Expression analysis of therapeutical response in Triple Negative Breast tumors.

Project description:10 biopsies before treatment from triple negative patients with complete response were collected. Total RNA was extracted from tumor specimens and the whole transcriptome was quantified with Affymetrix HuGene1.1ST. The biopsies were classified into Good (major or complete) or Poor (absent or minor) therapeutic response subgroup. Whole genome expression of triple negative breast cancer tissues were measured before neoadjuvant chemotherapy

2016-03-24 | E-GEOD-45898 | biostudies-arrayexpress